Lead sponsor
AriBio Co., Ltd.
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
1
Ongoing
1,745
Total enrollment
218
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Phase 3
1
Trials by status
Active, not recruiting
1
Completed
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)Amyloid biomarker required (PET)Ph 3Active, not recruiting1,535
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed210